Video

Dr. Riedell on an Analysis Evaluating the Effect of Time to Relapse on OS in MCL

Peter Riedell, MD, discusses the patient population and design of a dynamic landmark analysis conducted in patients with mantle cell lymphoma.

Peter Riedell, MD, assistant professor of medicine, University of Chicago Medicine, discusses the patient population and design of a dynamic landmark analysis conducted in patients with mantle cell lymphoma (MCL). 

The analysis focused on evaluating the effect of time to relapse on OS in adult patients with MCL who were treated with up to 2 lines of rituximab (Rituxan)-based induction therapy, followed by frontline autologous stem cell transplantation (ASCT), according to Riedell. In an effort to include a homogenous population, the analysis only included patients who underwent ASCT within 1 year of their diagnosis, Riedell explains. Patients who were transplanted between 2000 and 2018 were evaluated, Riedell adds.

Primary end points included overall survival (OS) and post-relapse OS, Riedell adds. The dynamic landmark analysis was employed at 6-month intervals to evaluate the effects of relapse on OS while adjusting for pertinent patient- and disease-related variables, Riedell concludes.

Related Videos
James J. Harding, MD, associate attending physician, Memorial Sloan Kettering Cancer Center
J. Bradley Elder, MD
Rimas V. Lukas, MD
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Diane Reidy-Lagunes, MD, vice chair, Oncology Operations, Regional Care Network, Memorial Sloan Kettering Cancer Center
Shubham Pant, MD, MBBS
Kevin Kalinsky, MD, MS, professor, Department of Hematology and Medical Oncology, director, Division of Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine; Louisa and Rand Glenn Family Chair in Breast Cancer Research, director, Glenn Family Breast Center, director, Breast Medical Oncology, Winship Cancer Institute of Emory University
Brett L. Ecker, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Yelena Y. Janjigian, MD, chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center